Christian Zwingelstein
Overview
Explore the profile of Christian Zwingelstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
452
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Weathers S, Rood-Breithaupt J, de Groot J, Thomas G, Manfrini M, Penas-Prado M, et al.
Neurooncol Adv
. 2021 Oct;
3(1):vdab141.
PMID: 34693288
Background: There is an urgent need for additional therapies to treat recurrent glioblastoma (GBM). Preclinical studies suggest that high dose macitentan, an oral dual endothelin receptor antagonist, enhances the cytotoxic...
2.
Dale G, Halabi A, Petersen-Sylla M, Wach A, Zwingelstein C
Antimicrob Agents Chemother
. 2018 Jul;
62(9).
PMID: 30012756
This open-label, nonrandomized, single-dose, phase 1 study evaluated the pharmacokinetics and safety of murepavadin, a novel peptide antibiotic for the treatment of serious infections. The study was conducted in 32...
3.
Guerard N, Oder D, Nordbeck P, Zwingelstein C, Morand O, Welford R, et al.
Clin Pharmacol Ther
. 2017 Jul;
103(4):703-711.
PMID: 28699267
Lucerastat is a glucosylceramide synthase inhibitor aimed at reducing production of glycosphingolipids (GSLs), including those accumulating in Fabry disease. The safety, tolerability, pharmacodynamics, and pharmacokinetics of oral lucerastat were evaluated...
4.
Guerard N, Zwingelstein C, Dingemanse J
J Clin Pharmacol
. 2017 Jun;
57(11):1425-1431.
PMID: 28618006
Lucerastat, an inhibitor of glucosylceramide synthase, has the potential for substrate reduction therapy in glycosphingolipid storage disorders such as Fabry disease. In pharmacokinetic studies in rats, dogs, and healthy subjects,...
5.
Guerard N, Zwingelstein C, Hoch M, Dingemanse J
Basic Clin Pharmacol Toxicol
. 2015 Nov;
118(5):356-68.
PMID: 26525450
Ponesimod, a selective S1P1 receptor modulator, is a potential therapeutic agent for autoimmune disorders. The impact of hepatic or renal impairment on the pharmacokinetics, safety and tolerability of ponesimod and...
6.
Schmitt E, Riwanto M, Sambandamurthy V, Roggo S, Miault C, Zwingelstein C, et al.
Angew Chem Int Ed Engl
. 2011 May;
50(26):5889-91.
PMID: 21563281
No abstract available.
7.
Wunderink R, Laterre P, Francois B, Perrotin D, Artigas A, Vidal L, et al.
Am J Respir Crit Care Med
. 2011 Feb;
183(11):1561-8.
PMID: 21297074
Rationale: Severe community-acquired pneumonia (sCAP) is a leading cause of death worldwide. Adjunctive therapies for sCAP are needed to further improve outcome. A systemic inhibitor of coagulation, tifacogin (recombinant human...
8.
Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors
Jahnke W, Blommers M, Fernandez C, Zwingelstein C, Amstutz R
Chembiochem
. 2005 Jul;
6(9):1607-10.
PMID: 16028302
No abstract available.
9.
Abraham E, Reinhart K, Opal S, Demeyer I, Doig C, Rodriguez A, et al.
JAMA
. 2003 Jul;
290(2):238-47.
PMID: 12851279
Context: The expression and release of tissue factor is a major trigger for the activation of coagulation in patients with sepsis. Tissue factor pathway inhibitor (TFPI) forms a complex with...